- Home
- FATE vs DMO Comparison
FATE vs DMO Comparison
Compare FATE & DMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FATE | DMO |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 123.3M |
| IPO Year | 2013 | 2009 |
Fundamental Metrics
Financial Performance| Metric | FATE | DMO |
|---|---|---|
| Price | $1.25 | $10.98 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 37.3K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,646,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $10.42 |
| 52 Week High | $1.94 | $12.11 |
Technical Indicators
Market Signals| Indicator | FATE | DMO |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 48.74 |
| Support Level | $0.95 | $10.90 |
| Resistance Level | $1.30 | $11.37 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 14.89 | 23.76 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.